Dr. William Oh on How Precision Medicine and Early Detection Transform Outcomes in Prostate Cancer Care
In part one of a two-part series on prostate cancer, the Precision Medicine Podcast addresses critical challenges as well as new advancements in prostate cancer, the second leading cause of cancer-related deaths in men. Host, Karan Cushman, is joined by Dr. William Oh, Director of Precision Medicine at Yale Cancer Center and Chair of the American Cancer Society National Prostate Cancer Roundtable. Together, in this Part 1 they shed light on the complexities of prostate cancer and how early screening can address rising incidence rates and persistent disparities, particularly among African American men.
Interested in sponsoring
the Podcast?
Contact our executive producer for programming and sponsorship details.
Prostate cancer currently affects one in eight men in the US, with African American men facing a one-in-six risk and 70% higher incidence rate than White men. These disparities extend to earlier onset and more aggressive disease presentations. Globally, the disease is the most frequently diagnosed cancer in 112 countries and a leading cause of cancer-related deaths in 48 countries. The incidence of prostate cancer has been rising steadily. There has been a 3% annual increase in cases and a 5% annual rise in advanced prostate cancer diagnoses since 2014. Throughout the series, Dr. Oh discusses the role precision medicine can play in addressing these trends by tailoring prevention, diagnosis and treatment strategies to individual patient profiles.
Karan and Dr. Oh begin the conversation by highlighting critical advances in prostate cancer care, including the development of over a dozen FDA-approved drugs in recent decades.
Listeners will learn of the systemic barriers that often prevent men from accessing these treatments, resulting in just half of men with advanced prostate cancer receiving standard-of-care therapies—a fact that underscores the need to improve access and equity in treatment.
Dr. Oh chairs the American Cancer Society National Prostate Cancer Roundtable, which aims to address these gaps by uniting diverse stakeholders—from patient advocacy groups to scientific organizations—to improve outcomes through collaborative efforts.
The discussion also explores the role of environmental and epigenetic factors in prostate cancer risk. Dr. Oh discusses how stress, socioeconomic disparities, and toxic exposures, such as those experienced by 9/11 first responders, may alter DNA and increase cancer risk. He compares these findings to the higher incidence of prostate cancer among African American men who live in environments that exacerbate health disparities. Dr. Oh emphasizes the importance of identifying and mitigating these risks to improve outcomes.
Screening is a key topic throughout the conversation, and Dr. Oh discusses the challenges of early detection and the controversies surrounding PSA (prostate specific antigen) screening. While current guidelines recommend baseline PSA testing for most men between the ages of 50 to 55, new evidence supports earlier screening for high-risk populations, particularly African American men who should begin testing between ages 40 and 45. This shift toward earlier detection is critical for addressing aggressive cancers before they progress to advanced stages.
Dr. Oh goes on to explain the importance of genetic testing, which reveals up to 10% of advanced prostate cancer cases involve BRCA or other DNA repair mutations. Recognizing these mutations early can inform targeted treatments like PARP inhibitors, yet Dr. Oh notes that many patients are not tested, underscoring the need for better implementation of precision diagnostics. By linking genetic data to clinical outcomes, precision medicine can help tailor treatments to the unique needs of each patient.
The episode concludes with a call to action for improved education and collaboration. Dr. Oh emphasizes the need for patients to discuss family history and risk factors with their doctors and for primary care physicians to prioritize early conversations about prostate health. He advocates for a comprehensive approach that combines education, technology and multidisciplinary care to close gaps in prostate cancer treatment and ensure that advances in precision medicine benefit all populations, especially those at highest risk.
Stay tuned for Part 2 coming out in late December 2024.
Download the full transcript of the episode here (pdf).
Like what you hear? Please spread the joy...
-
Share the Precision Medicine Podcast with your friends
-
Leave a review and subscribe in your favorite podcast app!
-
Follow us on Twitter @PMPbyTrapelo
-
Follow us on Linked In
Interested in sponsoring the Precision Medicine Podcast?
Don't miss the next episode...
About Our Guest
Dr. William Oh
Director of Precision Medicine, Yale Cancer Center
Dr. William K. Oh is Professor of Medicine in the Division of Medical Oncology and Director of Precision Medicine for Yale Cancer Center. He also serves as Medical Director of Smilow Cancer Hospital at Greenwich Hospital.
As Director of Precision Medicine for Yale Cancer Center and Smilow Cancer Hospital, he is focused on building a cohesive program in precision medicine, integrating basic and translational science, clinical trials, and Smilow Cancer Hospital’s Precision Medicine Tumor Board. He is committed to increasing the routine use of molecular and genetic testing for all patients with cancer, a goal he has been committed to throughout his career.
Dr. Oh is a genitourinary oncologist with decades of experience caring for patients with prostate cancer. Before his appointment at Yale, Dr. Oh served as the Chief Medical Officer and Executive Vice President of the Prostate Cancer Foundation, where he focused on barriers to the delivery of care for prostate cancer nationally. Dr. Oh led an expert panel that synthesized the evidence and published guidelines for prostate cancer screening for Black men in the US, which was published in 2024 in NEJM Evidence. He was also Chief Medical Officer of Sema4, a publicly traded genomics and health intelligence company that developed AI tools to help doctors make better clinical decisions for patients.
From 2009-2020, Dr. Oh was System Chief of Hematology and Medical Oncology at Mount Sinai Health System as well as Deputy Director of the Tisch Cancer Institute from 2017-2020. Prior to joining Mount Sinai, Dr. Oh advanced from Instructor to Associate Professor of Medicine at Harvard Medical School and was Clinical Director of the Lank Center for Genitourinary Oncology at Dana Farber Cancer Institute.
Dr. Oh also serves as Chair of the American Cancer Society’s National Prostate Cancer Roundtable, as a member of the Board of Trustees and Chair of the Medical Advisory Council for the Chemotherapy+ Foundation. He has participated on grant review committees for multiple National Institutes of Health, National Cancer Institute, and Foundation grants, and has served on guidelines panels for the American Urological Association and American Society of Clinical Oncology. He has participated on multiple journal editorial boards. Dr. Oh has published nearly 400 peer-reviewed publications and book chapters in genitourinary oncology and is a frequently invited lecturer at national and international meetings. He is an inductee of American Society for Clinical Investigation and has been continuously selected as a Top Doctor in New York Magazine, Castle Connolly, Best Doctors and Super Doctors from 2010 to 2024. He was recently honored as a Top AAPI Doctor in 2023 and 2024.
Dr. Oh completed his undergraduate degree at Yale University, received his medical degree from New York University School of Medicine, and did his internship and residency at Brigham and Women’s Hospital before his clinical fellowship in medical oncology at Dana-Farber Cancer Institute.